Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:MRNA News 6 January 2026 - 14 January 2026

Moderna stock (MRNA) slips in premarket after 17% surge — here’s what investors are watching next

Moderna stock (MRNA) slips in premarket after 17% surge — here’s what investors are watching next

New York, January 14, 2026, 05:03 (ET) — Premarket Moderna shares fell roughly 1% in early trading Wednesday, following a strong jump the previous session. The stock stood at $39.20, down 40 cents from Tuesday’s close of $39.60. (Investing.com) This move is crucial as Moderna struggles to reassure investors it can establish steady footing now that demand for COVID shots has dropped. The market has shown little tolerance for vaccine makers missing their own demand forecasts, even slightly. This week’s price volatility raises the stakes on upcoming numbers and timelines. Traders are watching closely to confirm if cost cuts hold
14 January 2026
····
Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next

Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next

New York, January 13, 2026, 11:31 EST — Regular session Moderna shares were up $3.97, or 11.7%, at $37.81 by late morning in New York, lifting the vaccine maker to one of the stronger movers in biotech trading. The bounce comes as investors try to pin down what “post-pandemic Moderna” looks like — smaller, more volatile, and still dependent on seasonal vaccine demand that can shift fast. The company’s early look at 2025 is being read as a test of whether the slide has finally slowed. Moderna said it expects about $1.9 billion in 2025 sales, near the top end
13 January 2026
····
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 13.01.2026

LIVEMarkets rolling coverageStarted: January 13, 2026, 12:00 AM ESTUpdated: January 13, 2026, 11:58 PM EST WHSP Holdings Insider Buying Reaches AU$3.4 Million, Led by Robert Millner January 13, 2026, 11:58 PM EST. WHSP Holdings Limited (ASX: SOL) saw insider buying over the past 12 months, led by Robert Millner with an AU$3.4 million purchase at AU$34.48 a share. The current price is about AU$38.00, suggesting purchases near the prevailing level. There were no insider sales in the period. Insiders own 5.4% of the company, worth around AU$782 million at latest prices, a sign of alignment with other shareholders. While such
13 January 2026
·········
Moderna stock slides as $1.9 billion sales view fails to calm investors (MRNA)

Moderna stock slides as $1.9 billion sales view fails to calm investors (MRNA)

NEW YORK, Jan 12, 2026, 10:25 (ET) — Regular session Moderna (MRNA.O) shares dropped roughly 4% on Monday following the release of updated revenue and expense forecasts ahead of a healthcare investor event. The stock fell $1.38 to $32.92, after starting the day at $34.40 and fluctuating between $35.77 and $32.81. This update is crucial as Moderna works to transition from its COVID windfall to a more reliable lineup of seasonal vaccines. Investors are focused on whether the company’s cost-cutting efforts will provide enough runway for upcoming approvals and late-stage trial results. Vaccination demand jitters have sent the stock spinning,
12 January 2026
·····
Moderna (MRNA) stock slips after $1.9B 2025 revenue view and cost cuts — what to watch next

Moderna (MRNA) stock slips after $1.9B 2025 revenue view and cost cuts — what to watch next

New York, January 12, 2026, 09:55 EST — Regular session Moderna (MRNA.O) shares dropped about 2% to $33.60 early Monday after the biotech forecasted around $1.9 billion in revenue for 2025 and lowered its GAAP operating-expense forecast for that year—the U.S. accounting standard. The stock swung between $35.77 and $33.33 in a volatile session. (ACCESS Newswire) This update is crucial as Moderna strives to reassure investors it can sustain itself on seasonal vaccine revenues and an expanding pipeline, rather than relying on pandemic-era demand. Traders are fixated on cash levels and how quickly the company is cutting expenses. The timing
12 January 2026
·····
Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

New York, January 7, 2026, 09:54 EST — Regular session Pfizer shares rose about 0.9% to $25.67 in morning trade on Wednesday, even as investors weighed a new patent lawsuit tied to its COVID-19 vaccine and a cautious call from UBS. UBS began coverage of Pfizer with a Neutral rating and a $25 price target, pointing to what it described as revenue uncertainty as several big drugs face patent expirations in coming years. UBS estimated roughly $15 billion to $20 billion of annual revenue is exposed to loss of exclusivity — when patents expire and cheaper rivals move in —
7 January 2026
······
S&P 500 2026 Forecast: 7,490 Target Meets a Data Test as Earnings Season Nears

S&P 500 2026 Forecast: 7,490 Target Meets a Data Test as Earnings Season Nears

NEW YORK, January 7, 2026, 06:01 EST — Premarket Strategists polled by Reuters see the S&P 500 at 7,490 by end-2026, implying gains of just over 9% from end-2025 as investors weigh Fed succession, election risk and the durability of the AI boom. A slim majority—56%—also forecast a market correction in the coming months. “The most under-appreciated tail risk for 2026 is that the Fed eases monetary policy more than economic conditions justify, inadvertently reigniting inflation,” said Lale Akoner, a global market strategist at eToro. Reuters Wall Street closed higher on Tuesday, with the S&P 500 up 0.62% at 6,944.82,
7 January 2026
·······
Dow Jones futures tread water near 50,000 as jobs data looms after record close

Dow Jones futures tread water near 50,000 as jobs data looms after record close

New York, Jan 7, 2026, 06:22 ET — Premarket Dow Jones futures were little changed on Wednesday, with the March e-mini contract up 5 points, or 0.01%, at 49,726 by 5:35 a.m. ET. Futures are contracts that track an index before the cash market opens. Investing.com The Dow Jones Industrial Average closed Tuesday up 0.99% at 49,462.08, a record, keeping the 50,000 milestone in view. Chip-related shares climbed on fresh artificial-intelligence optimism and Moderna surged after Bank of America lifted its price target, as investors positioned for a run of labor data after a 43-day federal government shutdown; the S&P
7 January 2026
········
Moderna stock slides premarket after 11% surge on flu vaccine filings — what investors watch next

Moderna stock slides premarket after 11% surge on flu vaccine filings — what investors watch next

New York, January 7, 2026, 05:25 EST — Premarket Moderna (MRNA) shares fell 1.4% to $35.15 in premarket trading on Wednesday, after jumping 10.9% in the previous session to close at $35.66. The stock hit an intraday high of $36.26 on Tuesday, with about 20.2 million shares traded. StockAnalysis The moves follow Moderna’s announcement on Monday that it has filed for marketing authorization — regulatory approval to sell — for its messenger RNA (mRNA) seasonal influenza vaccine, mRNA-1010, in the United States, Europe, Canada and Australia. Moderna said the filings were backed by Phase 3 data showing relative vaccine efficacy
7 January 2026
····
Dow Jones breaks above 49,000 in record close as chip-led rally rolls on

Dow Jones breaks above 49,000 in record close as chip-led rally rolls on

New York, Jan 6, 2026, 17:09 EST — After-hours The Dow Jones Industrial Average closed above 49,000 for the first time on Tuesday, extending Wall Street’s early-year run as technology shares drove broad gains. The Dow added 484.90 points, or 1%, to 49,462.08; the S&P 500 rose 0.6% to 6,944.82 and the Nasdaq climbed 0.6% to 23,547.17. AP News For investors, the round-number break puts immediate focus on whether the index can hold those levels and make a run at 50,000. With earnings season nearing, traders are looking for proof that the latest rally has enough follow-through to survive the
6 January 2026
··········
Dow nears 50,000 as Nvidia CES remarks ignite SanDisk, Micron surge and lift Wall Street

Dow nears 50,000 as Nvidia CES remarks ignite SanDisk, Micron surge and lift Wall Street

NEW YORK, Jan 6, 2026, 15:16 EST U.S. stocks rose on Tuesday, lifting the Dow to a fresh record as chip and healthcare shares led gains. At about 2:30 p.m. ET, the Dow was up 1.02% at 49,476.54, while the S&P 500 gained 0.62% to 6,944.55 and the Nasdaq rose 0.61% to 23,537.96. SanDisk jumped 23% and Moderna climbed 10%; Argent Capital portfolio manager Jed Ellerbroek said he expects “a very strong earnings season for Big Tech” and higher capex, short for capital spending. Reuters The rally kept the S&P 500 within range of the record it set in late
6 January 2026
··············
Moderna stock jumps nearly 11% after BofA target lift; flu vaccine filing in focus

Moderna stock jumps nearly 11% after BofA target lift; flu vaccine filing in focus

NEW YORK, January 6, 2026, 12:28 EST — Regular session Shares of Moderna Inc (MRNA.O) were up 10.7% at $35.60 in midday trading on Tuesday after BofA Global Research raised its price objective on the vaccine maker. The stock touched a session high of $36.25. Reuters The jump comes as investors weigh whether Moderna can turn its mRNA platform into steadier, seasonal revenue after the post-pandemic drop in COVID-19 vaccine demand. Traders have been sensitive to shifts in sell-side views as the company leans on new product launches and tighter spending to narrow losses. On Monday, Moderna said it filed
6 January 2026
····
1 2 3 4

Stock Market Today

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 07.02.2026

7 February 2026
LIVEMarkets rolling coverageStarted: February 7, 2026, 12:00 AM ESTUpdated: February 7, 2026, 12:49 AM EST CSL Faces Growth Uncertainty Amid Seqirus Spin-off Pause and Flu Vaccine Demand Drop February 7, 2026, 12:49 AM EST. CSL (ASX:CSL) confronts near-term challenges after delaying its Seqirus vaccine unit spin-off due to weaker U.S. flu vaccination uptake, impacting its fiscal 2026 growth outlook. Regulatory scrutiny in Europe over its Tavneos kidney therapy data, plus intensifying U.S. competition for its Vifor iron products, heighten concerns over product credibility and pricing pressure. Despite these headwinds, CSL's diversified portfolio in plasma, vaccines, and kidney therapies underpins its
Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop